Please reload

Recent Posts

Hans Petter Tjeldflaat has joined Biovotec AS as part-time CFO on the 29th of February. Hans Petter has a broad experience from similar positions in s...

Hans Petter Tjeldflaat Joins Biovotec As Part-time CFO

March 3, 2016

1/1
Please reload

Featured Posts

Biovotec AS Extends The Board With 2 New Additions

September 16, 2016

In an Extraordinary General Assembly held on the 16th of September, the shareholders have decided to extend the board consisting of Terje Hannisdahl and Harald Magnus Andreassen with Trond Gjelsten and Mårten Wigstøl.

 

Mårten Wigstøl has extensive knowledge in the field of Biotech and Medtech, and has been on the board, chairman of board and CEO in many Biotech/Medtech companies during his 26 years industry experience, bringing with him a well of operational, financial and strategic experience. 

 

Trond Gjelsten represents Biovotec’s second largest shareholder Tjeld AS.
He has over 15 years track record with international sales and business development. 

 

“I am proud that we could attract Mårten to the board. We are all very much looking forward working with him. Mårten taking over as chairman will allow me to reduce my Biovotec workload somewhat, but still be very much engaged during this very exciting time for us", says Terje Hannisdahl. “The change strengthens the board's commercial experience, in line with Biovotec's first advanced wound healing product (DermeRep®) launch in 2018."

 

Mårten is also excited about the potential future of Biovotec and impressed about the progress so far,

“I am delighted to be nominated to the Biovotec Board as a Chairman. I have followed Biovotec from the outside for some time and I am very impressed by the progress management have done so far. The company has a scalable technology platform with a low production cost that can be used in many applications. Biovotec’s current core focus on hard to heal wounds is addressing a large and escalating challenge  in our health system, partly due to lifestyle diseases like diabetes. As standard wound care is expensive and healthcare budgets are under pressure everywhere, there is demand for  both more efficient and cost effective treatments.

Mårten then added,

Biovotec’s products, that are much more cost effective than other products on the market, have already shown some superior preclinical results. I am confident that the company is well positioned to become a major player in the large and growing wound healing market and I am looking to be part of this journey.”

Please reload

Follow Us

I'm busy working on my blog posts. Watch this space!

Please reload

Search By Tags
Please reload

Archive
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

Engebrets vei 3, 0275 Oslo, Norway                                                   © Biovotec AS                                                                       info@biovotec